| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Brands | $2.36B | $2.36B | $2.17B | $2.12B | $2.28B | $2.44B | $2.35B | $2.33B |
| Generics | $1.42B | $1.38B | $1.35B | $1.13B | $1.28B | $1.31B | $1.34B | $1.18B |
| Lipitor | $348.4M | $375.6M | $355.9M | $388M | $387.9M | $396.1M | $377.3M | $462M |
| Norvasc | $161.9M | $168.9M | $166.2M | $172.3M | $182.7M | $179.7M | $175.2M | $210M |
| Lyrica ® | $124.3M | $129.9M | $127M | $112.6M | $128.1M | $126.5M | $119.8M | $120.6M |
| EpiPen® Auto-Injectors | $115.5M | $123.2M | $73.1M | $96.7M | $136.8M | $157.2M | $79M | $101.1M |
| Creon ® | $78.2M | $84.6M | $90.4M | $82.4M | $91.4M | $93.1M | $98.9M | $97.4M |
| Viagra ® | $106.1M | $100.2M | $88.6M | $98.5M | $100.3M | $105.2M | $104.2M | $95M |
| Zoloft ® | $58.9M | $60.6M | $58.2M | $60.2M | $61.1M | $66.8M | $66.8M | $72.6M |
| Celebrex ® | $72.2M | $74.1M | $67.1M | $63.4M | $70M | $73.3M | $66.2M | $67.1M |
| Yupelri ® | $54.5M | $62.2M | $66.6M | $58.3M | $66.6M | $71.4M | $70.6M | $62.5M |
| Effexor ® | $62.7M | $66.3M | $64.5M | $59.3M | $63.1M | $67.2M | $68.1M | $62M |
| Xalabrands | $45.6M | $41.2M | $37.1M | $37.1M | $40.7M | $38.6M | $42M | $39.2M |
| Dymista ® | $55M | $43.5M | $41.3M | $42.8M | $48.4M | $33.8M | $38.6M | $37.3M |
| Xanax ® | $35.4M | $38.6M | $36.5M | $32.3M | $33.9M | $34.2M | $39.5M | $34.8M |
| Total | $3.8B | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.7B | $3.52B |